Company Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.
Prothena Corporation plc has a license, development, and commercialization agreement with F.
Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
The company was founded in 2012 and is based in Dublin, Ireland.
| Country | IE |
| IPO Date | Dec 18, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 173 |
| CEO | Dr. Gene G. Kinney Ph.D. |
Contact Details
Address: 77 Sir John Rogerson’s Quay Dublin, IE | |
| Website | https://www.prothena.com |
Stock Details
| Ticker Symbol | PRTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001559053 |
| CUSIP Number | G72800108 |
| ISIN Number | IE00B91XRN20 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gene G. Kinney Ph.D. | President, Chief Executive Officer & Director |
| Brandon S. Smith | Chief Operating Officer |
| David A. Ford | Chief People Officer |
| Michael J. Malecek | Chief Legal Officer |
| Tran B. Nguyen M.B.A. | Chief Financial Officer & Chief Strategy Officer |
| Carol D. Karp | Chief Regulatory Officer |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Karin L. Walker CPA | Chief Accounting Officer & Controller |
| Mark C. Johnson C.F.A. | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 03, 2024 | 4 | Filing |